Repligen Buys BioLife for $1.5 Billion
Repligen agreed to acquire BioLife Solutions for approximately $1.5 billion in enterprise value, using 64% stock and 36% cash. BioLife’s CryoStor biopreservation media supports 18 approved therapies and a majority of U.S. commercially sponsored…
